New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 59, Issue 4, 2015, Pages 420-438

  Maffioli, L ^a   Florimonte, L ^b   Costa, D C ^c   Castanheira, J Correia ^c   Grana, C ^d   Luster, M ^e   Bodei, L ^d   Chinol, M ^d  

^a Legnano Hospital   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c CHAMPALIMAUD CENTRE FOR THE UNKNOWN   (Portugal)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Anticarcinogenic agents; Prostate specific antigen; Prostatic neoplasms; Radiopharmaceuticals; Radium Ra 223 dichloride

Indexed keywords

BOMBESIN; RADIOPHARMACEUTICAL AGENT; RADIUM CHLORIDE RA 223; SAMARIUM 153; STRONTIUM 89;

ARTICLE; BLOOD TOXICITY; BONE PAIN; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CHEMORADIOTHERAPY; DIARRHEA; DRUG DISTRIBUTION; EXPERIENCE; FATIGUE; HUMAN; MALE; NAUSEA; NONHUMAN; PALLIATIVE THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RADIATION SAFETY; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); VOMITING; ANALGESIA; ANIMAL; BONE; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIATION RESPONSE;

ANIMALS; BONE AND BONES; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PAIN MANAGEMENT; PALLIATIVE CARE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOPHARMACEUTICALS;

EID: 84945119633     PISSN: 18244785     EISSN: 18271936     Source Type: Journal    
DOI: None     Document Type: Article

References (106)

1. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide. Sources, methods and major patterns in GLOBOCAN 2012. IntJ Cancer 2015;136:E359-86.
2. Horwich A, Parker C, De Reijke T. et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol 2013;24(Suppl. 6):106-14.
3. NCCN Guidelines for Patients: Prostate Cancer Version 1.2015. Fort Washington: National Comprehensive Cancer Network®. [Internet] Available from: http://www.nccn.org/patients/guidelines/prostate/[cited on 2015, Sept 15].
4. Scher HI, Buchanan G, Gerald W et al. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 2004;11:459-76.
5. Baur B, Solbach C, Andreolli E et al. Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A"-DTPA-DUPA-Pep. Pharmaceuticals (Basel) 2014;7:517-29.
6. 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. T Nucl Med 2006;47:1144-52.
7. Abi-Ghanem AS, Me Grath MA, Jacene HA. Radionuclide therapy for osseous metastases in prostate cancer. Semin Nucl Med 2015;45:66-80.
8. Blacksburg SRI, Witten MR, Haas JA. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases. Curr Treat Options Oncol 2015; l6:325.
9. Body JJ, Casimiro S, Costa L. Targeting bone metastases in prostate cancer: improving clinical outcome. Nat Rev Urol 2015;12:340-56.
10. Parker C, Nilsson S, Heinrich D et al. Alpha emitter Radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23.
11. Guerra Liberal FD, Tavares AA, Tavares JM. Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods. Med Phys 20l4; 4l: ll4l01.
12. Rubini G, Nicoletti A, Rubini D et al. Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium. Cancer Biother Radiopharm 2014;29:1-11.
13. Han SH, De Klerk JM, Tan S et al. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186) Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med 2002;43:1150-6.
14. Maxon HR 3rd, Schroder LE, Hertzberg VS et al. Rhenium-186 (Sn) HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med 1991;32:1877-81.
15. Liepe K, Runge R, Kotzerke J. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J Cancer Res Clin Oncol 2005;131:60-6.
16. 89Sr in the treatment of painful skeletal metastasis. Nucl Med Commun 2007;28:623-30.
17. 89Sr vs !53Sm EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun 2007;28:245-50.
18. Den RB, Doyle LA, Knudsen E. Practical guide to the use of radium 223 dichloride. Can J Urol 2014;21(suppl. 1):70-6.
19. Blake GM, Zivanovic MA, Blaquiere RM et al. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. J Nucl Med 1988;29:549-57.
20. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 2005;6:392-400.
21. Mertens WC, Stitt L, Porter AT. Strontium 89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: a dose response relationship? Am J Clin Oncol 1993;16:238-42.
22. Porter AT, McEwan AJ, Powe JE et al. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805-13.
23. Sciuto R, Maini CL, Tofani A et al. Radiosensitization with low dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89. Nucl Med Commun 1996;17:799-804.
24. 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002;43:79-86.
25. Tu SM, Millikan RE, Mengistu B et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet 2001;357:336-41.
26. Quilty PM, Kirk D, Bolger JJ et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31:33-40.
27. Oosterhof GO, Roberts JT, De Reijke TM et al. Strontium (89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003;44:519-26.
28. Bayouth JE, Macey DJ, Kasi LP et al. Dosimetry and Toxicity of Samarium-153-EDTMP Administered for Bone Pain Due to Skeletal Metastases. J Nucl Med 1994;35:63-9.
29. Anderson P. Samarium for Osteoblastic Bone Metastases and Osteosarcoma. Expert Opin Pharmacother 2006;11:1475-86.
30. Hirabayashi H, Fujisaki J. Bone-Specific Drug Delivery Systems. Clin Pharmacokinet 2003;42:1319-30.
31. Roque M, Martinez MJ, Alonso P et al. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev 2003;4, CD003347.
32. Serafini AN, Houston SJ, Resche I et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998;16:1574-81.
33. Sartor O, Reid RH, Hoskin PJ et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormonerefractory prostate cancer. Urology 2004;63:940-5.
34. 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 2007;34:1023-30.
35. 153Sm-EDTMP and docetaxel administerd sequentially to patients with metastatic castration-resistant prostate cancer. Nucl Med Comm 2014;35:88-94.
36. Borsò E Mazzarri S, Boni G et al. The SAMDOCET study: !53Sm-EDTMP and Docetaxel versus Docetaxel in Taxane-naïve patients with metastatic castration-refractory prostate cancer. Eur J Nucl Med 2013;40(Suppl 2):S4W.
37. 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: A retrospective analysis. J Nucl Med 2011;52:1721-6.
38. 177Lu-labeled methylene diphosphonate, in Molecular Imaging and Contrast Agent Database (MICAD).. Bethesda, MD: National Center for Biotechnology Information, © 2004-2013 [Internet] Available from: http://www.ncbi.nlm.nih.gov/books/NBK56203 [cited on 2015, Sep. 15].
39. Joshi DP, Seery WH, Goldberg LG et al. Evaluation of phosphorus-32 for intractable pain secondary to prostatic carcinoma metastases. JAMA 1965;193:621-623.
40. Paes FM, Serafini AN. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med 2010;40:89-104.
41. Srivastava SC, Atkins HL, Krishnamurthy GT et al. Treatment of metastatic bone pain with tin-117m Stannic diethylene triamine penta-acetic cid: A phase I/II clinical study. Clin Cancer Res 1998;4:61-8.
42. Yuan J, Liu C, Liu X et al. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: A phase II study. Clin Nucl Med 2013;38:88-92.
43. Zolghadri S, Jalilian AR, Yousefnia H et al. Development of l66Holmiumrl, 2 Propylene Di-amino Tetra (Methylene phosphonic acid) as a Possible Bone Palliation Agent. World J Nucl Med 2014;13:28-33.
44. Das T, Chakraborty S, Sarma HD et al. 170Tm-EDTMP: a potential cost-effective alternative to (89) SrCl (2) for bone pain palliation. Nucl Med Biol 2009;36:561-8.
45. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225-39.
46. Hirao M, Hashimoto J, Yamasaki N et al. Oxygen tension is an important mediator of the transformation of osteoblasts to osteocytes. J Bone Mineral Metab 2007;25:266-76.
47. Barensden GW Responses of cultured cells, tumors and normal tissues to radiations of different linear energy transfer. In: Ebert M, Howard A, editors. Current Topics in Radiation Research. Volume IV Amsterdam, Netherlands: North-Holland; 1968. pp. 293-356.
48. Tinganelli W, Ma NY, Von Neubeck C et al. Influence of acute hypoxia and radiation quality on cell survival. J Radiat Res 2013;54(Suppl. 1):i23-30.
49. 89Sr in mice. J Nucl Med 2003;44:252-9.
50. Wright HA, Magee JL, Hamm RN et al. Calculations of physical and chemical reactions produced in irradiated water containing DNA. Radiat Prot Dosimetry 1985;13:133-6.
51. Kampf G. Induction of DNA double-strand breaks by ionizing radiation of different quality and their relevance for cell inactivation. Radiobiol Radiother (Berl) 1988;29:631-58.
52. Raju MR, Eisen Y, Carpenter S et al. Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus. Radiat Res 1991;128:204-9.
53. Sgouros G, Roeske JC, McDevitt MR et al. MIRD pamphlet no. 22 (abridged): Radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med 2010;51:311-28.
54. Henriksen G, Bruland ØS, Larsen RH. Thorium and actinium polyphosphonate compounds as bone seeking alpha particleemitting agents. Anticancer Res 2004;24:101.
55. Tiepolt C, Grüning T, Franke WG. Renaissance of 224Ra for the treatment of ankylosing spondylitis: clinical experiences. Nucl Med Commun. 2002;23:61-6.
56. Nilsson S, Larsen RH, Foss SD et al. First Clinical Experience with A-Emitting Radium-223 in the Treatment of Skeletal Metastases. Clin Cancer Res 2005;11:4451-9.
57. 223Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2013;40:1384
58. Xofigo (radium Ra 223 dichloride) injection: prescribing information. US FDA;.[Internet] Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/2039711bl.pdf [cited on 2015, Sept 15].
59. Xofigo: summary of product characteristics. European Medicines Agency; [Internet], Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002653/WC500156l72.pdf [cited on 2015, Sept 15].
60. 223Ra-chloride: dose to normal organs and tissues Eur J Nucl Med Mol Imaging 2013;40:207-12.
61. Nilsson S, Franzen L, Parker C et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8:587-594.
62. Highlights of prescribing information, Xofigo (radium Ra 223dichloride) Injection, for intravenous use. US Food and Drug Administration; [Internet], Available from: www.accessdata.fda.gov/drugsatfda-docs/label/2013/2039711bl.pdf [cited on 2015, Sep. 15]
63. Xofigo product information, U. S. Xofigo Web site [Internet], Available from: http://www.xofigo-us.com/patient/index.php [cited on 2015, Sep. 15].
64. 2de in men with castrationresistant prostate cancer. Health Phys 2014;106:494-504.
65. Pandit-Taskar N, Larson SM, Carrasquillo JA. Bone-Seeking Radiopharmaceuticals for Treatment of Osseous Metastases, Part 1: a Therapy with 223Ra-Dichloride. J Nucl Med 2014;55:268-74.
66. Sonpavde G, Pond GR, Berry WR et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol 2012;30:607-13.
67. Nilsson S, Strang P, Aksnesr AK et al. A randomized, doseresponse, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 2012:48:678-86.
68. Parker CC, Pascoe S, Chodacki A et al. A randomized, doubleblind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castrationresistant prostate cancer. Eur Urol 2013;63:189-97.
69. Hoskin P, Sartor O, O'Sullivan JM et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. 2014;15:1397-406.
70. Sartor O, Coleman R, Nilsson S et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014;15:738-46.
71. Nilsson S, Sartor O, Bruland OS et al. Pain analysis from the phase III randomized ALSYMPCA study with radium-223dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases [abstract], J Clin Oncol 2013;31(Suppl.6):5038.
72. Castanheira C, Oliveira C, Gil N et al. Dicloreto de Radio-223 no tratamento de metastases osseas de cancro da prostataresistente a castragao - introdugao na pratica clinica em Portugal (2015) PO 00006 (Abstract Book, ONCOLOGY SPRING MEETING, EVORA); [Internet], Available from: http://encontrosdaprimavera.c0m/index.php/abstracts 0sters-medic0s [cited on 2015, Sep. 15].
73. U. S. National Institutes of Health. Clinical Trial.gov; [Internet], Available from https://clinicaltrials.gov/ct2/results?term=r adium&show-down=Y [cited on 2015, Sep. 15].
74. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-35.
75. Israeli RS, Powell CT, Corr JG et al. Expression of the prostatespecific membrane antigen. Cancer Res 1994;54:1807-11.
76. Wright GL Jr, Haley C, Beckett ML et al. Expression of prostatespecific membrane antigen (PSMA) in normal, benign and malignant prostate tissues. Urol Oncol 1995;1:18-28.
77. Rosenthal SA, Haseman MK, Polascik TJ. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Techniques in Urology 2001;7:27-37.
78. Troyer JK, Beckett ML, Wright GL Jr. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 1997;30:232-42.
79. Liu H, Moy P, Kim S et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57:3629-34.
80. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. Cancer Res 2000;60:5237-43.
81. Hamilton A, King S, Liu H et al. A novel humanized antibody against prostate specific membrane antigen (PSMA) for in vivo targeting and therapy. Proc Am Assoc Cancer Res 1998;39:440.
82. Bander NH, Milowsky MI, Nanus DM et al. Phase I trial of 177lu-tetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23:4591-601.
83. Tagawa ST, Milowsky MI, Morris M et al Phase II study of lutetium-177 labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castrationresistant prostate cancer. Clin Cancer Res 2013;18:5182-91.
84. Tagawa ST, Akhtar NH, Nikolopoulou A et al. Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody J591 in men with metastatic castration-resistant prostate cancer. Front Oncol 2013;3:214.
85. Santoni M, Scarpelli M, Mazzucchelli R et al. Targeting Prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. Journal of Biological Regulators and Homeostatic Agents 2014;28:555-63.
86. 68Ga generators. Appl Radiat Isot 2013;76:24-30.
87. 68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals 2014;7:779-96.
88. 131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy Eur J Nucl Med Mol Imaging 2014;41:1280-92.
89. 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014;41:11-20.
90. Kulkarni H, Wester HJ, Baum RP. Diagnosis and follow-up of recurring and metastatic prostate cancer by Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography. World J Nucl Med 2015; l4(Suppl 1):S36.
91. Benesova M, Schafer M, Bauder-Wiist U et al. Linker modifications of DOTA-conjugated inhibitors of the prostate-specific membrane antigen (PSMA). Eur J Nucl Med Mol Imaging 2013;40(Suppl 2):S281.
92. 177Lu-PSMA6l7. World J Nucl Med 2015;14(Suppl 1):S29.
93. 177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:987-8.
94. Baum RP, Kulkarni H, Schuchardt C et al. Theranostics of prostate cancer (PRLT) using Ga-68 and Lu-177 labeled prostatespecific membrane antigen small molecule. A new horizon for nuclear medicine. World J Nucl Med 2015;14(Suppl 1):S33.
95. McDonald TJ, Jornvall H, Tatemoto K. Identification and characterization of variant forms of the gastrin-releasing peptide (GRP). FEBS Lett 1983;156:349-56.
96. Tweedle MF. Peptide-targeted diagnostics and radiotherapeutics. Accounts Chem Res 2009;42:958-68.
97. 177Lu-AMBA: synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. T Nucl Med 2006;47:1144-52.
98. Bodei L, Ferrari M, Nunn A et al. 177Lu-AMBA bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S221.
99. Zhang H, Chen J, Waldherr C et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 2004;64:6707-15.
100. 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med 2013;54:867-72.
101. Nock BA, Maina T, Krenning EP et al. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting. J Nucl Med 2014;55:121-7.
102. Barbet J, Kraeber-Bodere F, Vuillez JP et al. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm 1999;14:153-66.
103. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999;59:1152-9.
104. Yu Z, Ananias HJ, Carlucci G et al. An update of radiolabeled bombesinn analogs for gastrin-releasing peptide receptor targeting. Curr Pharm Des 2013;19:3329-41.
105. Eder M, Schäfer M, Bauder-Wiist U et al. Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. The Prostate 2014;74:659-68.
106. Stott Reynolds TJ, Schehr R, Liu D et al Characterization and evaluation of DOTA-conjugated bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy. Nucl Med Biol 2015;42:99-108.